BNTC Benitec Biopharma Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1808898 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-18.4%
TTM EPS YoY4.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-37.6%
ROA-36.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.3%
Debt / equity0.00x
Current ratio19.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-23.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q42025-06-30 | 2025Q32025-03-31 | 2024Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | $0 | $0 | — | $0 | $0 |
| R&D expense | $8.62M | $7.89M | $6.30M | $5.83M | $3.37M | $2.87M | $6.50M | $5.38M |
| SG&A expense | $5.86M | $6.54M | $7.28M | $7.54M | $6.43M | $6.97M | $8.84M | $5.42M |
| Operating income | -$14.48M | -$14.43M | -$13.58M | -$13.38M | -$9.80M | -$9.83M | -$15.34M | -$10.80M |
| Net income | -$12.93M | -$12.81M | -$11.94M | -$11.84M | -$8.96M | -$8.80M | -$14.50M | -$9.55M |
| EBITDA | -$14.46M | -$14.41M | -$13.57M | -$13.36M | -$9.79M | -$9.82M | -$15.32M | -$10.79M |
| EPS (basic) | -0.26 | — | -0.24 | -0.26 | -0.22 | -0.21 | -0.38 | -0.26 |
| EPS (diluted) | -0.26 | — | -0.24 | -0.26 | -0.22 | -0.21 | -0.38 | -0.26 |
| Weighted avg. shares (diluted) | 49.49M | — | 49.39M | 45.97M | 41.52M | 41.16M | 38.60M | 37.25M |
| Balance sheet | ||||||||
| Cash & equivalents | $176.37M | $179.97M | $184.76M | $188.79M | $94.59M | $97.86M | $103.45M | $78.34M |
| Current assets | $178.10M | $181.69M | $186.02M | $189.59M | $95.08M | $98.52M | $104.01M | $78.71M |
| PP&E, net | $110,000 | $178,000 | $116,000 | $115,000 | $118,000 | $131,000 | $145,000 | $151,000 |
| Total assets | $179.10M | $182.62M | $187.00M | $190.68M | $96.03M | $99.59M | $105.21M | $79.07M |
| Current liabilities | $9.08M | $5.34M | $3.27M | $2.80M | $2.02M | $1.80M | $7.03M | $3.09M |
| Total liabilities | $9.45M | $5.61M | $3.67M | $3.32M | $2.43M | $2.30M | $7.64M | $3.13M |
| Shareholders' equity | $169.65M | $177.01M | $183.33M | $187.36M | $93.60M | $97.30M | $97.57M | $75.94M |
| Shares outstanding | 34.89M | 34.42M | 34.35M | 34.25M | 26.25M | 26.25M | 25.55M | 23.45M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.62M | -$4.94M | -$4.45M | -$3.78M | -$3.35M | -$8.21M | -$3.09M | -$7.70M |
| Capital expenditure | — | $79,000 | $15,000 | — | — | $0 | $6,000 | — |
| Free cash flow | — | -$5.02M | -$4.47M | — | — | -$8.21M | -$3.09M | — |
| Investing cash flow | $0 | -$79,000 | -$15,000 | -$11,000 | $0 | $0 | -$6,000 | -$12,000 |
| Financing cash flow | $0 | $241,000 | $506,000 | $98.23M | $0 | $2.54M | $28.41M | $17.87M |
| Depreciation & amortization | $17,000 | $17,000 | $14,000 | $14,000 | $13,000 | $14,000 | $13,000 | $14,000 |
| Stock-based compensation | $5.51M | $6.26M | $7.59M | $7.38M | $5.18M | $13.45M | $7.74M | $3.14M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.